EXACT Sciences — Q3 2024 Earnings Presentation
20 slides from EXACT Sciences's earnings presentation, Nov 5, 2024
Slide 1: Third-quarter 2024 earnings call
Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. Third-quarter 2024 earnings call November 5, 2024 EXACT SCIENCES 1
Slide 2: Safe harbor and non-GAAP disclosures
Safe harbor and non-GAAP disclosures This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are sub
Slide 3: Exact Sciences is a leader in advanced cancer diagnostics
Exact Sciences is a leader in advanced cancer diagnostics OUR TEAM OUR FLAGSHIP TESTS Q3 RESULTS 500 1.2M Record total revenue of $709M, 13% core revenue growth R&D team members test results in 3Q24 1,400 Adj. EBITDA of $99M, or 14% margin rate, and record free cash flow of $113M person commercial t
Slide 4: Core revenue grew 13% in 3Q24
Core revenue grew 13% in 3Q24 Core revenue Screening revenue Precision Oncology core revenue $707M $626M +13% $545M $472M +15% $154M $162M +5% 3Q23 3Q24 3Q23 3Q24 3Q23 3Q24 Please refer to our third-quarter 2024 earnings release at exactsciences.com for discussion of non-GAAP financial measures and
Slide 5: Profitability continued to improve and free cash flow reached an all-time high
Profitability continued to improve and free cash flow reached an all-time high Adjusted EBITDA Free cash flow Adjusted EBITDA margin $113M $99M 14% +$42M +500 bps $56M 9% +$113M 3Q23 3Q24 -$1M 3Q23 3Q24 Please refer to our third-quarter 2024 earnings release at exactsciences.com for discussion of no
Slide 6: Updated 2024 guidance
Updated 2024 guidance guidance ∆ at Y/Y ∆ at Prior guidance Nov. 5 update midpoint midpoint Total revenue $2.810 - 2.850B $2.730 - 2.750B -$90M +10% Screening $2.155 - 2.175B $2.080 - 2.095B -$78M +12% Precision Oncology $655 - 675M $650 - 655M -$13M +4% Adj. EBITDA $335 - 355M $310 - 320M -$30M +44
Slide 7: Magnifying the impact of our advanced tests through the ExactNexus technology platform
Magnifying the impact of our advanced tests through the ExactNexus technology platform via data, tools, and AI Patients Improve patient ~24M patient experience records Increase long-term adherence Payers Health systems Enable electronic test 800+ in-network 370+ electronic ordering & resulting agree
Slide 8: Strong precision oncology foundation creates growth opportunity to detect residual and recurrent disease
Strong precision oncology foundation creates growth opportunity to detect residual and recurrent disease Progress with Oncodetect and upcoming milestones Assessing risk of recurrence Accepted publication Detecting in peer-reviewed journal recurrence earlier Present multiple data sets in 2025 to expa
Slide 9: A new performance standard in noninvasive screening
A new performance standard in noninvasive screening TM Progress with Cologuard Plus and upcoming milestones Received FDA approval 95% cancer sensitivity Establish higher price through Medicare pathway 94% specificity Launch with Medicare coverage and guideline inclusion in 2025 43% lesion sensitivit
Slide 10: Working to bring the best blood-based colon cancer screening test to patients
Working to bring the best blood-based colon cancer screening test to patients Progress with blood-based CRC test and upcoming milestones Presented algorithm setting data at ESMO 88% cancer sensitivity Complete additional analytical studies 90% specificity Present pivotal BLUE-C study results in 2025
Slide 11: Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment
Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment EXACT SCIENCES 11
Slide 12: EXACT SCIENCES
EXACT SCIENCES 12
Slide 13: Condensed Consolidated Statements of Operations
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Operations (Amounts in thousands, except per share data) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Revenue $ 708,655 $ 628,338 $ 2,045,443 $ 1,852,881 O
Slide 14: Condensed Consolidated Balance Sheets
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Balance Sheets (Amounts in thousands) September 30, December 31, 2024 2023 Assets Cash and cash equivalents $ 588,830 $ 605,378 Marketable securities 432,301 172,266 Accounts receivable, net 264,819 203,623 In
Slide 15: Reconciliation of Core Revenue
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of Core Revenue (Amounts in thousands) GAAP Three Months Ended September 30, 2024 2023 % Change Screening $ 544,901 $ 472,013 15 % Precision Oncology 163,754 156,325 5 % Total $ 708,655 $ 628,338 13 % Non-GAAP Three M
Slide 16: Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations (Amounts in thousands) Three Months Ended September Nine Months Ended September 30, 30, 2024 2023 2024 2023 Revenue $ 708,655 $ 628,338 $ 2,045,443 $ 1,852,881 Cost of
Slide 17: EBITDA and Adjusted EBITDA Reconciliations
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information EBITDA and Adjusted EBITDA Reconciliations (Amounts in thousands) Three Months Ended September Nine Months Ended September 30, 30, 2024 2023 2024 2023 Net income (loss) $ (38,236) $ 794 $ (164,272) $ (154,383) Interest expense (1) 9
Slide 18: Reconciliation of U.S. GAAP to Non-GAAP Measures
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of U.S. GAAP to Non-GAAP Measures (Amounts in thousands) Three Months Ended September 30, 2024 Research & General & Amortization of Development Sales & Marketing Administrative acquired intangiible Impairment of Other
Slide 19: Reconciliation of U.S. GAAP to Non-GAAP Measures
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of U.S. GAAP to Non-GAAP Measures (Amounts in thousands) Three Months Ended September 30, 2023 Research & General & Amortization of Development Sales & Marketing Administrative acquired intangiible Impairment of Other
Slide 20: Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow (Amounts in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Net cash provided by operating activiti